Western blot analyses revealed that knockdown of NUP62 or NUP214 to ∼25% of control levels resulted from treatment of TOV112D cells (derived from a high grade ovarian carcinoma [41]) with combinations of targeted siRNAs (Fig. 1A). This evidence concerns the gene NUP62 and ovarian carcinoma.